What is claimed is:

1. A PPF polypeptide ~~comprising an amino acid sequence of Formula (VII):~~

~~Xaa_1-Xaa_2-Pro-Xaa_4-Pro-Xaa_6-His-Pro-Xaa_9-Xaa_{10}~~
~~Xaa_{11}-Xaa_{12}-Xaa_{13}-Xaa_{14}-Xaa_{15}-Xaa_{16}-Xaa_{17}-Ala-Xaa_{19}-Tyr~~
~~Xaa_{21}-Xaa_{22}-Xaa_{23}-Leu-Xaa_{25}-Xaa_{26}-Xaa_{27}-Xaa_{28}-Xaa_{29}-Xaa_{30}~~
~~Xaa_{31}-Thr-Arg-Gln-Arg-Tyr~~

~~wherein:~~

~~Xaa_1 is Tyr or absent;~~
~~Xaa_2 is Ile, Pro, or absent;~~
~~Xaa_4 is Lys, BH-modified Lys, Ala, Ser, or Arg;~~
~~Xaa_6 is Glu, Gln, Ala, Asn, Asp, or Val;~~
~~Xaa_9 is Gly or Ala;~~
~~Xaa_{10} is Glu, Ala, Asp, Asn, Gln, Gly, Pro, or Aib;~~
~~Xaa_{11} is Glu, Ala, Asp, Asn, Gln, Gly, Pro, or Aib;~~
~~Xaa_{12} is Ala or Pro;~~
~~Xaa_{13} is Ser or Pro;~~
~~Xaa_{14} is Pro, Ala, or Ser;~~
~~Xaa_{15} is Glu, Ala, Asp, Asn, Gln, Gly, Pro, or Aib;~~
~~Xaa_{16} is Glu or Asp;~~
~~Xaa_{17} is Leu or Ile;~~
~~Xaa_{19} is Arg, Lys, BH-modified Lys, Gln, or N(Me)Ala;~~
~~Xaa_{21} is Tyr, Ala, Phe, Lys, or BH-modified Lys;~~
~~Xaa_{22} is Ala or Ser;~~
~~Xaa_{23} is Ser, Ala, or Asp;~~
~~Xaa_{25} is Arg, Lys or BH-modified Lys;~~
~~Xaa_{26} is His, Ala, or Arg;~~
~~Xaa_{27} is Tyr, or Phe;~~
~~Xaa_{28} is Leu or Ile;~~
~~Xaa_{29} is Asn, or Gln;~~
~~Xaa_{30} is Leu or Met; and~~
~~Xaa_{31} is Val, Ile, or Leu;~~
~~wherein said polypeptide comprises~~ comprising the amino acid sequence of SEQ ID NO: 438.

~~2. A PPF polypeptide according to claim 1 wherein said PPF polypeptide further comprises one or more insertions.~~

~~3~~2. ~~A~~ The PPF polypeptide according to ~~any one of~~ claims 1 ~~and 2~~, wherein said PPF polypeptide further comprises an N-terminal cap.

43. ~~A~~ The PPF polypeptide according to ~~any one of~~ claims 1 or~~,~~ 2~~, and 3~~, wherein said polypeptide is linked to one or more water-soluble polymers.

54. The PPF polypeptide of claim 43, wherein said polymer is selected from at least one of the group consisting of polyethylene glycol and a fatty acid molecule, wherein said polymer is linked to the N- or C- terminus of the polypeptide, or the side chain of a lysine or serine amino acid residue within the sequence of the polypeptide.

65. Use of a PPF polypeptide of any one of claims 1 through ~~5~~ 4 in the manufacture of a medicament for altering body composition of a subject, wherein said medicament alters the fat to lean ratio, thereby altering body composition, wherein the PPF polypeptide is administered peripherally.

76. The use of claim 65, wherein body fat is reduced and lean body mass is maintained or increased.

87. The use of claim 76, wherein the body fat and lean body mass are measured as percent body fat and percent lean body mass, respectively.

98. The use of any one of claims 65, 76, and 87, wherein body composition is measured by a method selected from the group consisting of underwater weighing, air displacement plethysmograph, x-ray, MRI, DEXA scan, CT scans, and adiabatic bomb calorimetry.

109. The use of any one of claims ~~6~~ 5 through 98, wherein body weight is reduced.

~~11. The use of any one of claims 6 through 10, wherein the PPF polypeptide is to be administered peripherally.~~

~~12~~10. The use of any one of claims ~~6~~ 5 through ~~11~~9, wherein said medicament is to be administered with at least one agent selected from the group consisting of an amylin, amylin agonist or amylin analog agonist, salmon calcitonin, a cholecystokinin (CCK) or CCK agonist, a leptin (OB protein) or leptin agonist, an exendin or exendin analog agonist, a GLP-1, GLP-1 agonist or GLP-1 analog agonist, a CCK or CCK agonist, calcitonin, a calcitonin agonist, a small molecule cannabinoid CB1 receptor antagonist, rimonabant, an 11 beta-hydroxysteroid dehydrogenase-1 inhibitor, sibutramine, and phentermine.

~~13~~11. The use of any one of claims ~~6~~ 5 through ~~12~~10, wherein the subject is overweight or obese.

~~14~~12. The use of any one of claims ~~6~~ 5 through ~~13~~11, further comprising dieting.

~~15~~13. The use of any one of claims ~~6~~ 5 through ~~14~~12, wherein the subject is a mammal.

~~16~~14. The use of claim ~~15~~ 13 wherein the mammal is a human.

~~17~~15. The use of claim ~~15~~ 13 wherein the mammal is selected from a group consisting of a primate, a rat, a mouse, a cat, a dog, a pig, a cow, a steer, a horse, a sheep, and a goat.

~~18~~16. Use of a PPF polypeptide according to any one of claims 1 through ~~5~~ 4 in the manufacture of a medicament for ~~preferentially~~ lowering plasma triglyceride levels in a subject, wherein said medicament is to be administered to the subject, wherein cholesterol levels are lowered to a lesser extent, wherein the medicament is administered peripherally.

~~19~~17. The use of claim ~~18~~16, wherein triglyceride levels are lowered and cholesterol levels are not lowered.

~~20~~18. The use of claim ~~18~~16, wherein triglyceride levels are lowered and LDL cholesterol levels are not lowered.

~~21~~19. The use of claim ~~18~~16, wherein triglyceride levels are lowered and LDL cholesterol levels are lowered to a lesser extent.

~~22~~20. The use of claim ~~18~~16, wherein amylase levels are also lowered.

~~23~~21. Use of a PPF polypeptide according to any one of claims 1 through ~~5~~ 4 in the manufacture of a medicament for reducing body fat or body fat gain in a subject while maintaining or increasing lean body mass, wherein the medicament is administered peripherally.

~~24~~22. Use of a PPF polypeptide according to any one of claims 1 through ~~5~~ 4 in the manufacture of a medicament for reducing central body fat and for preserving or increasing lean body mass, wherein the medicament is administered peripherally.

~~25~~23. Use of a PPF polypeptide according to any one of claims 1 through ~~5~~ 4 in the manufacture of a medicament for increasing fatty acid β-oxidation while preserving or increasing lean body mass in a subject, wherein the medicament is administered peripherally.

~~26~~24. Use of a PPF polypeptide according to any one of claims 1 through ~~5~~ 4 in the manufacture of a medicament for treating nonalcoholic steatohepatitis or lipodystrophy in a subject, wherein the medicament is administered peripherally.